Amyloid Aβ levels in Alzheimer's disease - A diagnostic tool and the key to understanding the natural history of Aβ?

Journal of Alzheimer's Disease

Volumn 3, Issue 3, 2001, Pages 305-312

  McLean, Catriona A ^a,b   Beyreuther, Konrad ^a,b,c   Masters, Colin L ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; PRESENILIN 1; PRESENILIN 2; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; DISEASE ASSOCIATION; HUMAN; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DETERMINATION; PROTEIN SYNTHESIS;

EID: 0034977636     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2001-3305     Document Type: Article

References (71)

1. The presenilins in Alzheimer's disease - Proteolysis holds the key
2. Amyloid diseases: Abnormal protein aggregation in neurodegeneration
3. Science, medicine, and the future - Alzheimer's disease
4. Amyloid and lipids in the pathology of Alzheimer disease
5. Translating cell biology into therapeutic advances in Alzheimer's disease
6. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
7. Amyloid β protein gene: cDNA, mRNA distribution and genetic linkage near the Alzheimer locus
8. Alzheimer's disease amyloid precursor protein (AbPP): Proteolytic processing, secretases and βA4 amyloid production
9. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor
10. Constitutive and regulated a-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease
11. Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity
12. β-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE
13. Polarized sorting of β-amyloid precursor protein and its proteolytic products in MDCK cells is regulated by two independent signals
14. Distinct sites of intracellular production for Alzheimer's disease a-β-40/42 amyloid peptides
15. Alzheimer's Aβ(1-42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells
16. The β-amyloid domain is essential for axonal sorting of amyloid precursor protein
17. Release of excess amyloid β protein from a mutant amyloid β protein precursor
18. An increased percentage of long amyloid β protein secreted by familial amyloid β protein precursor (βAPP717) mutants
19. A new pathogenic mutation in the APP gene (1716V) increases the relative proportion of Ab42(43)
20. A mutation in codon 717 of the amyloid precursor protein gene in an Australian family with Alzheimer's disease
21. Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid β-protein precursor
22. Presenilin structure, function and role in Alzheimer disease
23. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein
24. A presenilin-1-dependent g-secretase-like protease mediates release of Notch intracellular domain
25. The proteolytic fragments of the Alzheimer's disease-associated presenilin-1 form heterodimers and occur as a 100-150-kDa molecular mass complex
26. Mapping the APP/presenilin (PS) binding domains: The hydrophilic N-terminus of PS2 is sufficient for interaction with APP and can displace APP/PS1 interaction
27. Apolipoprotein E affects the rate of Alzheimer disease expression: β-Amyloid burden is a secondary consequence dependent on APOE genotype and duration disease
28. Alpha-2 macroglobulin is genetically associated with Alzheimer disease
29. Biochemical evidence for the long-tail form (Ab1-42/43) of amyloid β protein as a seed molecule in cerebral deposits of Alzheimer's disease
30. Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome
31. Amyloid β-protein (Aβ) accumulation in the putamen and mammillary body during aging and in Alzheimer-disease
32. Quantitation of amyloid β-protein (Aβ) in the cortex during aging and in Alzheimer's disease
33. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease
34. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline
35. Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease
36. The levels of soluble versus insoluble brain Aβ distinguish Alzheimer's disease from normal and pathologic aging
37. Appearance of sodium dodecyl sulfate-stable amyloid β-protein (Aβ) dimer in the cortex during aging
38. Presence of sodium dodecyl sulfate-stable amyloid β-protein dimers in the hippocampus CA1 not exhibiting neurofibrillary tangle formation
39. Alzheimer disease PS-1 exon 9 deletion defined
40. A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1
41. The nonfibrillar amyloid β-peptide induces apoptotic neuronal cell death: Involvement of its C-terminal fusogenic domain
42. A molecular model of Alzheimer amyloid β-peptide fibril formation
43. Endogenous proteins controlling amyloid β-peptide polymerization - Possible implications for β-amyloid formation in the central nervous system and in peripheral tissues
44. Distribution and fluidizing action of soluble and aggregated amyloid β-peptide in rat synaptic plasma membranes
45. Interactions of amyloid β-peptide (1-40) with ganglioside-containing membranes
46. Solution structures of micelle-bound amyloid β-(1-40) and β-(1-42) peptides of Alzheimer's disease
47. Intracellular accumulation of insoluble, newly synthesized Aβn-42 in amyloid precursor protein-transfected cells that have been treated with Aβ1-42
48. Alzheimer's disease-associated presenilin 1 in neuronal cells - Evidence for localization to the endoplasmic reticulum-golgi intermediate compartment
49. Intracellular production of βA4 amyloid of Alzheimer's disease: Modulation by phosphoramidon and lack of coupling to the secretion of the amyloid precursor
50. Intracellular and secreted Alzheimer β-amyloid species are generated by distinct mechanisms in cultured hippocampal neurons
51. Intraneuronal Aβ42 accumulation in human brain
52. Caspase-6 role in apoptosis of human neurons, amyloidogenesis, and Alzheimer's disease
53. Expression of β-amyloid precursor protein-CD3γ chimeras to demonstrate the selective generation of amyloid β1-40 and amyloid β1-42 peptides within secretory and endocytic compartments
54. Protein kinase C-dependent a-secretase competes with β-secretase for cleavage of amyloid-β precursor protein in the trans-Golgi network
55. Candidate γ-secretases in the generation of the carboxyl terminus of the Alzheimer's disease βA4 amyloid: Possible involvement of cathepsin D
56. Mutagenesis identifies new signals for β-amyloid precursor protein endocytosis, turnover, and the generation of secreted fragments, including Aβ42
57. Amyloid precursor protein, although partially detergent-insoluble in mouse cerebral cortex, behaves as an atypical lipid raft protein
58. Morphology and toxicity of Aβ-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease
59. Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons
60. Cerebrospinal fluid β-amyloid(1-42) in Alzheimer disease - Differences between early- and late-onset Alzheimer disease and stability during the course of disease
61. Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF
62. Analysis of heterogeneous β-A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive western blot assay
63. Cerebrospinal fluid Aβ42 is increased early in sporadic Alzheimer's disease and declines with disease progression
64. Plasma and cerebrospinal fluid levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease
65. CSF beta-amyloid cognition, and APOE genotype in Alzheimer's disease
66. Three-year follow-up of cerebrospinal fluid tau, β-amyloid 42 and 40 concentrations in Alzheimer's disease
67. Amyloid plaques in cerebellar cortex and the integrity of Purkinje cell dendrites
68. Collection and normal levels of the amyloid precursor protein in plasma
69. Plasma amyloid β-peptide 1-42 and incipient Alzheimer's disease
70. Isolation, chemical characterization, and quantitation of Aβ 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits
71. Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome